1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Multiple Sclerosis - Pipeline Review, H1 2016

Multiple Sclerosis - Pipeline Review, H1 2016

  • June 2016
  • -
  • Global Markets Direct
  • -
  • 903 pages

Multiple Sclerosis - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Multiple Sclerosis - Pipeline Review, H1 2016’, provides an overview of the Multiple Sclerosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Multiple Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Multiple Sclerosis
- The report reviews pipeline therapeutics for Multiple Sclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Multiple Sclerosis therapeutics and enlists all their major and minor projects
- The report assesses Multiple Sclerosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Multiple Sclerosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Multiple Sclerosis - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
Introduction 10
Multiple Sclerosis Overview 11
Therapeutics Development 12
Multiple Sclerosis - Therapeutics under Development by Companies 14
Multiple Sclerosis - Therapeutics under Investigation by Universities/Institutes 30
Multiple Sclerosis - Pipeline Products Glance 32
Multiple Sclerosis - Products under Development by Companies 36
Multiple Sclerosis - Products under Investigation by Universities/Institutes 56
Multiple Sclerosis - Companies Involved in Therapeutics Development 59
Multiple Sclerosis - Therapeutics Assessment 237
Drug Profiles 290
Multiple Sclerosis - Dormant Projects 828
Multiple Sclerosis - Discontinued Products 852
Multiple Sclerosis - Product Development Milestones 857
Appendix 868

List of Tables
Number of Products under Development for Multiple Sclerosis, H1 2016 46
Number of Products under Development for Multiple Sclerosis - Comparative Analysis, H1 2016 47
Number of Products under Development by Companies, H1 2016 49
Number of Products under Development by Companies, H1 2016 (Contd..1) 50
Number of Products under Development by Companies, H1 2016 (Contd..2) 51
Number of Products under Development by Companies, H1 2016 (Contd..3) 52
Number of Products under Development by Companies, H1 2016 (Contd..4) 53
Number of Products under Development by Companies, H1 2016 (Contd..5) 54
Number of Products under Development by Companies, H1 2016 (Contd..6) 55
Number of Products under Development by Companies, H1 2016 (Contd..7) 56
Number of Products under Development by Companies, H1 2016 (Contd..8) 57
Number of Products under Development by Companies, H1 2016 (Contd..9) 58
Number of Products under Development by Companies, H1 2016 (Contd..10) 59
Number of Products under Development by Companies, H1 2016 (Contd..11) 60
Number of Products under Development by Companies, H1 2016 (Contd..12) 61
Number of Products under Development by Companies, H1 2016 (Contd..13) 62
Number of Products under Development by Companies, H1 2016 (Contd..14) 63
Number of Products under Investigation by Universities/Institutes, H1 2016 64
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 65
Comparative Analysis by Late Stage Development, H1 2016 66
Comparative Analysis by Clinical Stage Development, H1 2016 67
Comparative Analysis by Early Stage Development, H1 2016 68
Comparative Analysis by Unknown Stage Development, H1 2016 69
Products under Development by Companies, H1 2016 70
Products under Development by Companies, H1 2016 (Contd..1) 71
Products under Development by Companies, H1 2016 (Contd..2) 72
Products under Development by Companies, H1 2016 (Contd..3) 73
Products under Development by Companies, H1 2016 (Contd..4) 74
Products under Development by Companies, H1 2016 (Contd..5) 75
Products under Development by Companies, H1 2016 (Contd..6) 76
Products under Development by Companies, H1 2016 (Contd..7) 77
Products under Development by Companies, H1 2016 (Contd..8) 78
Products under Development by Companies, H1 2016 (Contd..9) 79
Products under Development by Companies, H1 2016 (Contd..10) 80
Products under Development by Companies, H1 2016 (Contd..11) 81
Products under Development by Companies, H1 2016 (Contd..12) 82
Products under Development by Companies, H1 2016 (Contd..13) 83
Products under Development by Companies, H1 2016 (Contd..14) 84
Products under Development by Companies, H1 2016 (Contd..15) 85
Products under Development by Companies, H1 2016 (Contd..16) 86
Products under Development by Companies, H1 2016 (Contd..17) 87
Products under Development by Companies, H1 2016 (Contd..18) 88
Products under Development by Companies, H1 2016 (Contd..19) 89
Products under Investigation by Universities/Institutes, H1 2016 90
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 91
Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 92
Multiple Sclerosis - Pipeline by 4D Pharma Plc, H1 2016 93
Multiple Sclerosis - Pipeline by 4SC AG, H1 2016 94
Multiple Sclerosis - Pipeline by AB Science SA, H1 2016 95
Multiple Sclerosis - Pipeline by AbbVie Inc., H1 2016 96
Multiple Sclerosis - Pipeline by Ablynx NV, H1 2016 97
Multiple Sclerosis - Pipeline by Acorda Therapeutics, Inc., H1 2016 98
Multiple Sclerosis - Pipeline by Actelion Ltd, H1 2016 99
Multiple Sclerosis - Pipeline by Addex Therapeutics Ltd, H1 2016 100
Multiple Sclerosis - Pipeline by Adhaere Pharmaceuticals, Inc., H1 2016 101
Multiple Sclerosis - Pipeline by Aegis Therapeutics, LLC, H1 2016 102
Multiple Sclerosis - Pipeline by Affectis Pharmaceuticals AG, H1 2016 103
Multiple Sclerosis - Pipeline by AiCuris GmbH and Co. KG, H1 2016 104
Multiple Sclerosis - Pipeline by Alkermes Plc, H1 2016 105
Multiple Sclerosis - Pipeline by Alpha Cancer Technologies Inc., H1 2016 106
Multiple Sclerosis - Pipeline by Amarna Therapeutics B.V., H1 2016 107
Multiple Sclerosis - Pipeline by Anavex Life Sciences Corp., H1 2016 108
Multiple Sclerosis - Pipeline by Antisense Therapeutics Limited, H1 2016 109
Multiple Sclerosis - Pipeline by Antitope Limited, H1 2016 110
Multiple Sclerosis - Pipeline by Aphios Corporation, H1 2016 111
Multiple Sclerosis - Pipeline by Apitope International NV, H1 2016 112
Multiple Sclerosis - Pipeline by Arena Pharmaceuticals, Inc., H1 2016 113
Multiple Sclerosis - Pipeline by Argos Therapeutics, Inc., H1 2016 114
Multiple Sclerosis - Pipeline by Arrien Pharmaceuticals, LLC, H1 2016 115
Multiple Sclerosis - Pipeline by Artielle ImmunoTherapeutics, Inc., H1 2016 116
Multiple Sclerosis - Pipeline by Astellas Pharma Inc., H1 2016 117
Multiple Sclerosis - Pipeline by Asterias Biotherapeutics, Inc., H1 2016 118
Multiple Sclerosis - Pipeline by Atara Biotherapeutics, Inc., H1 2016 119
Multiple Sclerosis - Pipeline by Athersys, Inc., H1 2016 120
Multiple Sclerosis - Pipeline by Axxam SpA, H1 2016 121
Multiple Sclerosis - Pipeline by Baliopharm AG, H1 2016 122
Multiple Sclerosis - Pipeline by Bio-Cancer Treatment International Limited, H1 2016 123
Multiple Sclerosis - Pipeline by BioAegis Therapeutics, Inc., H1 2016 124
Multiple Sclerosis - Pipeline by BIOCAD, H1 2016 125
Multiple Sclerosis - Pipeline by Biocon Limited, H1 2016 126
Multiple Sclerosis - Pipeline by Biogen, Inc., H1 2016 127
Multiple Sclerosis - Pipeline by Biogenomics Limited, H1 2016 128
Multiple Sclerosis - Pipeline by Biokine Therapeutics Ltd., H1 2016 129
Multiple Sclerosis - Pipeline by Biomar Microbial Technologies, H1 2016 130
Multiple Sclerosis - Pipeline by Bionature E.A. Ltd., H1 2016 131
Multiple Sclerosis - Pipeline by Bioncotech Therapeutics S.L., H1 2016 132
Multiple Sclerosis - Pipeline by Bionovis SA, H1 2016 133
Multiple Sclerosis - Pipeline by Bionure Farma, S.L., H1 2016 134
Multiple Sclerosis - Pipeline by Biovista Inc., H1 2016 135
Multiple Sclerosis - Pipeline by Bird Rock Bio, Inc., H1 2016 136
Multiple Sclerosis - Pipeline by Bolder Biotechnology, Inc., H1 2016 137
Multiple Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc., H1 2016 138
Multiple Sclerosis - Pipeline by C4X Discovery Holdings PLC, H1 2016 139
Multiple Sclerosis - Pipeline by Caladrius Biosciences, Inc. , H1 2016 140
Multiple Sclerosis - Pipeline by CASI Pharmaceuticals Inc., H1 2016 141
Multiple Sclerosis - Pipeline by Catalyst Pharmaceuticals, Inc., H1 2016 142
Multiple Sclerosis - Pipeline by Celgene Corporation, H1 2016 143
Multiple Sclerosis - Pipeline by Cell Cure Neurosciences, Ltd., H1 2016 144
Multiple Sclerosis - Pipeline by Cell2B S.A. , H1 2016 145
Multiple Sclerosis - Pipeline by Cellceutix Corporation, H1 2016 146
Multiple Sclerosis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 147
Multiple Sclerosis - Pipeline by Cognosci, Inc., H1 2016 148
Multiple Sclerosis - Pipeline by Coherus BioSciences, Inc., H1 2016 149
Multiple Sclerosis - Pipeline by Commence Bio, Inc., H1 2016 150
Multiple Sclerosis - Pipeline by Compugen Ltd., H1 2016 151
Multiple Sclerosis - Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2016 152
Multiple Sclerosis - Pipeline by Critical Outcome Technologies Inc., H1 2016 153
Multiple Sclerosis - Pipeline by CuraVac, Inc., H1 2016 154
Multiple Sclerosis - Pipeline by Cyxone AB, H1 2016 155
Multiple Sclerosis - Pipeline by Dimerix Bioscience Pty Ltd, H1 2016 156
Multiple Sclerosis - Pipeline by Eisai Co., Ltd., H1 2016 157
Multiple Sclerosis - Pipeline by Endece, LLC, H1 2016 158
Multiple Sclerosis - Pipeline by Euroscreen S.A., H1 2016 159
Multiple Sclerosis - Pipeline by Evgen Pharma Plc, H1 2016 160
Multiple Sclerosis - Pipeline by Evotec AG, H1 2016 161
Multiple Sclerosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 162
Multiple Sclerosis - Pipeline by Flex Pharma, Inc., H1 2016 163
Multiple Sclerosis - Pipeline by Forward Pharma A/S, H1 2016 164
Multiple Sclerosis - Pipeline by FPRT Bio Inc., H1 2016 165
Multiple Sclerosis - Pipeline by Gemac, H1 2016 166
Multiple Sclerosis - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2016 167
Multiple Sclerosis - Pipeline by GeNeuro SA, H1 2016 168
Multiple Sclerosis - Pipeline by Genzyme Corporation, H1 2016 169
Multiple Sclerosis - Pipeline by GlaxoSmithKline Plc, H1 2016 170
Multiple Sclerosis - Pipeline by Glialogix, Inc., H1 2016 171
Multiple Sclerosis - Pipeline by Hansa Medical AB, H1 2016 172
Multiple Sclerosis - Pipeline by Hanwha Chemical Corporation, H1 2016 173
Multiple Sclerosis - Pipeline by Harbor Therapeutics, Inc., H1 2016 174
Multiple Sclerosis - Pipeline by HitGen LTD, H1 2016 175
Multiple Sclerosis - Pipeline by Hutchison MediPharma Limited, H1 2016 176
Multiple Sclerosis - Pipeline by Iltoo Pharma, H1 2016 177
Multiple Sclerosis - Pipeline by Immune Response BioPharma, Inc., H1 2016 178
Multiple Sclerosis - Pipeline by ImmuNext, Inc., H1 2016 179
Multiple Sclerosis - Pipeline by Immungenetics AG, H1 2016 180
Multiple Sclerosis - Pipeline by InDex Pharmaceuticals AB, H1 2016 181
Multiple Sclerosis - Pipeline by Innate Immunotherapeutics Ltd, H1 2016 182
Multiple Sclerosis - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 183
Multiple Sclerosis - Pipeline by Io Therapeutics, Inc., H1 2016 184
Multiple Sclerosis - Pipeline by Jyant Technologies, Inc., H1 2016 185
Multiple Sclerosis - Pipeline by Kadimastem Ltd., H1 2016 186
Multiple Sclerosis - Pipeline by Kadmon Corporation, LLC, H1 2016 187
Multiple Sclerosis - Pipeline by KAHR medical Ltd., H1 2016 188
Multiple Sclerosis - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016 189
Multiple Sclerosis - Pipeline by Kareus Therapeutics, SA, H1 2016 190
Multiple Sclerosis - Pipeline by Karo Pharma AB, H1 2016 191
Multiple Sclerosis - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 192
Multiple Sclerosis - Pipeline by Kezar Life Sciences, Inc., H1 2016 193
Multiple Sclerosis - Pipeline by Kineta, Inc., H1 2016 194
Multiple Sclerosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 195
Multiple Sclerosis - Pipeline by Lead Discovery Center GmbH, H1 2016 196
Multiple Sclerosis - Pipeline by LFB S.A., H1 2016 197
Multiple Sclerosis - Pipeline by Lipocure Ltd., H1 2016 198
Multiple Sclerosis - Pipeline by MacroGenics, Inc., H1 2016 199
Multiple Sclerosis - Pipeline by MAKScientific, LLC, H1 2016 200
Multiple Sclerosis - Pipeline by Mallinckrodt Plc, H1 2016 201
Multiple Sclerosis - Pipeline by Mapi Pharma Ltd., H1 2016 202
Multiple Sclerosis - Pipeline by Marathon Pharmaceuticals, LLC, H1 2016 203
Multiple Sclerosis - Pipeline by MedAnnex Ltd, H1 2016 204
Multiple Sclerosis - Pipeline by MedDay SA, H1 2016 205
Multiple Sclerosis - Pipeline by Medestea Research and Production S.p.A., H1 2016 206
Multiple Sclerosis - Pipeline by MedImmune, LLC, H1 2016 207
Multiple Sclerosis - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2016 208
Multiple Sclerosis - Pipeline by Merck KGaA, H1 2016 209
Multiple Sclerosis - Pipeline by Meta-IQ ApS, H1 2016 210
Multiple Sclerosis - Pipeline by Mitochon Pharmaceuticals, Inc., H1 2016 211
Multiple Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 212
Multiple Sclerosis - Pipeline by MorphoSys AG, H1 2016 213
Multiple Sclerosis - Pipeline by Neuralstem, Inc., H1 2016 214
Multiple Sclerosis - Pipeline by Neuren Pharmaceuticals Limited, H1 2016 215
Multiple Sclerosis - Pipeline by Neurotec Pharma SL, H1 2016 216
Multiple Sclerosis - Pipeline by New World Laboratories, Inc., H1 2016 217
Multiple Sclerosis - Pipeline by Novartis AG, H1 2016 218
Multiple Sclerosis - Pipeline by NovImmune SA, H1 2016 219
Multiple Sclerosis - Pipeline by Nuevolution AB, H1 2016 220
Multiple Sclerosis - Pipeline by Octapharma AG, H1 2016 221
Multiple Sclerosis - Pipeline by Omeros Corporation, H1 2016 222
Multiple Sclerosis - Pipeline by OncoImmune, Inc., H1 2016 223
Multiple Sclerosis - Pipeline by Opexa Therapeutics, Inc., H1 2016 224
Multiple Sclerosis - Pipeline by OPKO Health, Inc., H1 2016 225
Multiple Sclerosis - Pipeline by OSE Immunotherapeutics, H1 2016 226
Multiple Sclerosis - Pipeline by Parvus Therapeutics, Inc., H1 2016 227
Multiple Sclerosis - Pipeline by Peptinov SAS, H1 2016 228
Multiple Sclerosis - Pipeline by Pfenex Inc., H1 2016 229
Multiple Sclerosis - Pipeline by Pfizer Inc., H1 2016 230
Multiple Sclerosis - Pipeline by PharmaEssentia Corporation, H1 2016 231
Multiple Sclerosis - Pipeline by PharmatrophiX, Inc., H1 2016 232
Multiple Sclerosis - Pipeline by Pharmaxis Limited, H1 2016 233
Multiple Sclerosis - Pipeline by Pieris Pharmaceuticals, Inc., H1 2016 234
Multiple Sclerosis - Pipeline by Plexxikon Inc., H1 2016 235
Multiple Sclerosis - Pipeline by ProNoxis AB, H1 2016 236
Multiple Sclerosis - Pipeline by Prothena Corporation Plc, H1 2016 237
Multiple Sclerosis - Pipeline by Q Therapeutics, Inc., H1 2016 238
Multiple Sclerosis - Pipeline by ReceptoPharm, Inc., H1 2016 239
Multiple Sclerosis - Pipeline by RedHill Biopharma Ltd., H1 2016 240
Multiple Sclerosis - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2016 241
Multiple Sclerosis - Pipeline by Regenesance BV, H1 2016 242
Multiple Sclerosis - Pipeline by Resverlogix Corp., H1 2016 243
Multiple Sclerosis - Pipeline by ReveraGen BioPharma, Inc., H1 2016 244
Multiple Sclerosis - Pipeline by Rigel Pharmaceuticals, Inc., H1 2016 245
Multiple Sclerosis - Pipeline by SanBio, Inc., H1 2016 246
Multiple Sclerosis - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2016 247
Multiple Sclerosis - Pipeline by Sareum Holdings Plc, H1 2016 248
Multiple Sclerosis - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 249
Multiple Sclerosis - Pipeline by Sorrento Therapeutics, Inc., H1 2016 250
Multiple Sclerosis - Pipeline by Symic Biomedical, Inc., H1 2016 251
Multiple Sclerosis - Pipeline by Synthon Holdings BV, H1 2016 252
Multiple Sclerosis - Pipeline by Targazyme, Inc., H1 2016 253
Multiple Sclerosis - Pipeline by Teikoku Pharma USA, Inc., H1 2016 254
Multiple Sclerosis - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 255
Multiple Sclerosis - Pipeline by Therapix Biosciences Ltd, H1 2016 256
Multiple Sclerosis - Pipeline by TikoMed AB, H1 2016 257
Multiple Sclerosis - Pipeline by Toleranzia AB, H1 2016 258
Multiple Sclerosis - Pipeline by Topas Therapeutics GmbH, H1 2016 259
Multiple Sclerosis - Pipeline by TxCell SA, H1 2016 260
Multiple Sclerosis - Pipeline by Vaccinex, Inc., H1 2016 261
Multiple Sclerosis - Pipeline by Vakzine Projekt Management GmbH, H1 2016 262
Multiple Sclerosis - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 263
Multiple Sclerosis - Pipeline by Virogenomics BioDevelopment, Inc., H1 2016 264
Multiple Sclerosis - Pipeline by Vitae Pharmaceuticals, Inc., H1 2016 265
Multiple Sclerosis - Pipeline by VivaCell Biotechnology Espana S.L., H1 2016 266
Multiple Sclerosis - Pipeline by Xenetic Biosciences (UK) Limited, H1 2016 267
Multiple Sclerosis - Pipeline by XL-protein GmbH, H1 2016 268
Multiple Sclerosis - Pipeline by Yungjin Pharm. Co., Ltd., H1 2016 269
Multiple Sclerosis - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 270
Assessment by Monotherapy Products, H1 2016 271
Assessment by Combination Products, H1 2016 272
Number of Products by Stage and Target, H1 2016 274
Number of Products by Stage and Mechanism of Action, H1 2016 303
Number of Products by Stage and Route of Administration, H1 2016 321
Number of Products by Stage and Molecule Type, H1 2016 323
Multiple Sclerosis - Dormant Projects, H1 2016 862
Multiple Sclerosis - Dormant Projects (Contd..1), H1 2016 863
Multiple Sclerosis - Dormant Projects (Contd..2), H1 2016 864
Multiple Sclerosis - Dormant Projects (Contd..3), H1 2016 865
Multiple Sclerosis - Dormant Projects (Contd..4), H1 2016 866
Multiple Sclerosis - Dormant Projects (Contd..5), H1 2016 867
Multiple Sclerosis - Dormant Projects (Contd..6), H1 2016 868
Multiple Sclerosis - Dormant Projects (Contd..7), H1 2016 869
Multiple Sclerosis - Dormant Projects (Contd..8), H1 2016 870
Multiple Sclerosis - Dormant Projects (Contd..9), H1 2016 871
Multiple Sclerosis - Dormant Projects (Contd..10), H1 2016 872
Multiple Sclerosis - Dormant Projects (Contd..11), H1 2016 873
Multiple Sclerosis - Dormant Projects (Contd..12), H1 2016 874
Multiple Sclerosis - Dormant Projects (Contd..13), H1 2016 875
Multiple Sclerosis - Dormant Projects (Contd..14), H1 2016 876
Multiple Sclerosis - Dormant Projects (Contd..15), H1 2016 877
Multiple Sclerosis - Dormant Projects (Contd..16), H1 2016 878
Multiple Sclerosis - Dormant Projects (Contd..17), H1 2016 879
Multiple Sclerosis - Dormant Projects (Contd..18), H1 2016 880
Multiple Sclerosis - Dormant Projects (Contd..19), H1 2016 881
Multiple Sclerosis - Dormant Projects (Contd..20), H1 2016 882
Multiple Sclerosis - Dormant Projects (Contd..21), H1 2016 883
Multiple Sclerosis - Dormant Projects (Contd..22), H1 2016 884
Multiple Sclerosis - Dormant Projects (Contd..23), H1 2016 885
Multiple Sclerosis - Discontinued Products, H1 2016 886
Multiple Sclerosis - Discontinued Products (Contd..1), H1 2016 887
Multiple Sclerosis - Discontinued Products (Contd..2), H1 2016 888
Multiple Sclerosis - Discontinued Products (Contd..3), H1 2016 889
Multiple Sclerosis - Discontinued Products (Contd..4), H1 2016 890

List of Figures
Number of Products under Development for Multiple Sclerosis, H1 2016 46
Number of Products under Development for Multiple Sclerosis - Comparative Analysis, H1 2016 47
Number of Products under Development by Companies, H1 2016 48
Number of Products under Investigation by Universities/Institutes, H1 2016 64
Comparative Analysis by Late Stage Development, H1 2016 66
Comparative Analysis by Clinical Stage Development, H1 2016 67
Comparative Analysis by Early Stage Products, H1 2016 68
Assessment by Monotherapy Products, H1 2016 271
Assessment by Combination Products, H1 2016 272
Number of Products by Top 10 Targets, H1 2016 273
Number of Products by Stage and Top 10 Targets, H1 2016 273
Number of Products by Top 10 Mechanism of Actions, H1 2016 302
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 302
Number of Products by Top 10 Routes of Administration, H1 2016 320
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 320
Number of Products by Top 10 Molecule Types, H1 2016 322
Number of Products by Stage and Top 10 Molecule Types, H1 2016 322

Companies Mentioned
4D Pharma Plc
4SC AG
AB Science SA
AbbVie Inc.
Ablynx NV
Acorda Therapeutics, Inc.
Actelion Ltd
Addex Therapeutics Ltd
Adhaere Pharmaceuticals, Inc.
Aegis Therapeutics, LLC
Affectis Pharmaceuticals AG
AiCuris GmbH and Co. KG
Alkermes Plc
Alpha Cancer Technologies Inc.
Amarna Therapeutics B.V.
Anavex Life Sciences Corp.
Antisense Therapeutics Limited
Antitope Limited
Aphios Corporation
Apitope International NV
Arena Pharmaceuticals, Inc.
Argos Therapeutics, Inc.
Arrien Pharmaceuticals, LLC
Artielle ImmunoTherapeutics, Inc.
Astellas Pharma Inc.
Asterias Biotherapeutics, Inc.
Atara Biotherapeutics, Inc.
Athersys, Inc.
Axxam SpA
Baliopharm AG
Bio-Cancer Treatment International Limited
BioAegis Therapeutics, Inc.
BIOCAD
Biocon Limited
Biogen, Inc.
Biogenomics Limited
Biokine Therapeutics Ltd.
Biomar Microbial Technologies
Bionature E.A. Ltd.
Bioncotech Therapeutics S.L.
Bionovis SA
Bionure Farma, S.L.
Biovista Inc.
Bird Rock Bio, Inc.
Bolder Biotechnology, Inc.
BrainStorm Cell Therapeutics Inc.
C4X Discovery Holdings PLC
Caladrius Biosciences, Inc.
CASI Pharmaceuticals Inc.
Catalyst Pharmaceuticals, Inc.
Celgene Corporation
Cell Cure Neurosciences, Ltd.
Cell2B S.A.
Cellceutix Corporation
Chong Kun Dang Pharmaceutical Corp.
Cognosci, Inc.
Coherus BioSciences, Inc.
Commence Bio, Inc.
Compugen Ltd.
Connexios Life Sciences Pvt. Ltd.
Critical Outcome Technologies Inc.
CuraVac, Inc.
Cyxone AB
Dimerix Bioscience Pty Ltd
Eisai Co., Ltd.
Endece, LLC
Euroscreen S.A.
Evgen Pharma Plc
Evotec AG
F. Hoffmann-La Roche Ltd.
Flex Pharma, Inc.
Forward Pharma A/S
FPRT Bio Inc.
Gemac
Genervon Biopharmaceuticals, LLC
GeNeuro SA
Genzyme Corporation
GlaxoSmithKline Plc
Glialogix, Inc.
Hansa Medical AB
Hanwha Chemical Corporation
Harbor Therapeutics, Inc.
HitGen LTD
Hutchison MediPharma Limited
Iltoo Pharma
Immune Response BioPharma, Inc.
ImmuNext, Inc.
Immungenetics AG
InDex Pharmaceuticals AB
Innate Immunotherapeutics Ltd
Inovio Pharmaceuticals, Inc.
Io Therapeutics, Inc.
Jyant Technologies, Inc.
Kadimastem Ltd.
Kadmon Corporation, LLC
KAHR medical Ltd.
KaloBios Pharmaceuticals, Inc.
Kareus Therapeutics, SA
Karo Pharma AB
Karyopharm Therapeutics, Inc.
Kezar Life Sciences, Inc.
Kineta, Inc.
Kyorin Pharmaceutical Co., Ltd.
Lead Discovery Center GmbH
LFB S.A.
Lipocure Ltd.
MacroGenics, Inc.
MAKScientific, LLC
Mallinckrodt Plc
Mapi Pharma Ltd.
Marathon Pharmaceuticals, LLC
MedAnnex Ltd
MedDay SA
Medestea Research and Production S.p.A.
MedImmune, LLC
Meiji Seika Pharma Co., Ltd.
Merck KGaA
Meta-IQ ApS
Mitochon Pharmaceuticals, Inc.
Mitsubishi Tanabe Pharma Corporation
MorphoSys AG
Neuralstem, Inc.
Neuren Pharmaceuticals Limited
Neurotec Pharma SL
New World Laboratories, Inc.
Novartis AG
NovImmune SA
Nuevolution AB
Octapharma AG
Omeros Corporation
OncoImmune, Inc.
Opexa Therapeutics, Inc.
OPKO Health, Inc.
OSE Immunotherapeutics
Parvus Therapeutics, Inc.
Peptinov SAS
Pfenex Inc.
Pfizer Inc.
PharmaEssentia Corporation
PharmatrophiX, Inc.
Pharmaxis Limited
Pieris Pharmaceuticals, Inc.
Plexxikon Inc.
ProNoxis AB
Prothena Corporation Plc
Q Therapeutics, Inc.
ReceptoPharm, Inc.
RedHill Biopharma Ltd.
RegeneRx Biopharmaceuticals, Inc.
Regenesance BV
Resverlogix Corp.
ReveraGen BioPharma, Inc.
Rigel Pharmaceuticals, Inc.
SanBio, Inc.
Santhera Pharmaceuticals Holding AG
Sareum Holdings Plc
SK Biopharmaceuticals Co., Ltd.
Sorrento Therapeutics, Inc.
Symic Biomedical, Inc.
Synthon Holdings BV
Targazyme, Inc.
Teikoku Pharma USA, Inc.
Teva Pharmaceutical Industries Ltd.
Therapix Biosciences Ltd
TikoMed AB
Toleranzia AB
Topas Therapeutics GmbH
TxCell SA
Vaccinex, Inc.
Vakzine Projekt Management GmbH
Vertex Pharmaceuticals Incorporated
Virogenomics BioDevelopment, Inc.
Vitae Pharmaceuticals, Inc.
VivaCell Biotechnology Espana S.L.
Xenetic Biosciences (UK) Limited
XL-protein GmbH
Yungjin Pharm. Co., Ltd.
Zydus Cadila Healthcare Limited

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global phototherapy equipment market is projected to reach USD 583.4 million by 2021, growing at a CAGR of 4.5% during the forecast period of 2016 to 2021. This market is primarily driven by the huge ...

Antinuclear Antibody Test Market by Product, Technique, Disease, End User - Forecast to 2021

Antinuclear Antibody Test Market by Product, Technique, Disease, End User - Forecast to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global antinuclear antibody (ANA) testing market is expected to reach USD 1,476.1 million by 2021 from USD 823.5 million in 2016, at a CAGR of 12.4%. The global ANA testing market is segmented based ...

Interstitial Cystitis  - Market Insights, Epidemiology and Market Forecast-2023

Interstitial Cystitis  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Interstitial Cystitis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.